Every 10-Q that Coya Therapeutics, Inc. (COYA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COYA filings page.
Coya Therapeutics, Inc., a clinical-stage biotech focused on regulatory T cell–based therapies, reported continued operating losses while maintaining a solid cash position for the quarter ended June 30, 2026. Cash and cash equivalents were $43.2 million, with total assets of $47.3 million and total liabilities of $4.0 million, leaving stockholders’ equity at $43.3 million. Management expects this cash to fund operations into the second half of 2027.
For the three months ended June 30, 2026, collaboration revenue was $0.24 million, entirely from R&D services under the Dr. Reddy’s COYA 302 alliance. Operating expenses reached $7.3 million, driven by $5.0 million in research and development and $2.3 million in general and administrative costs. Net loss for the quarter was $6.6 million (or $0.28 per share), compared with $6.1 million a year earlier.
For the six‑month period, collaboration revenue totaled $0.49 million, while research and development and general and administrative expenses were $9.1 million and $6.0 million, respectively. Net loss for the six months was $13.8 million. The company added equity capital via a January 2026 private placement and put a $30.0 million at‑the‑market stock program in place. COYA 302, its lead ALS candidate, is in a Phase 2 trial and received FDA Fast Track Designation on May 11, 2026.
Coya Therapeutics reported a Q1 2026 net loss of $7.2 million, similar to the prior year, as it continues developing its Treg-focused therapies. Collaboration revenue from its Dr. Reddy’s ALS partnership was $0.25 million. Research and development spending was $4.1 million, while general and administrative costs reached $3.8 million, including a one-time $1.0 million stock-option modification charge. Cash and cash equivalents rose to $50.7 million, helped by an $11.1 million January 2026 private placement, and management expects this to fund operations into the second half of 2027. As a key pipeline milestone, the FDA granted Fast Track Designation to lead ALS candidate COYA 302.
Coya Therapeutics (COYA) reported Q3 results. Collaboration revenue was $3,564,254, driven by the DRL Development Agreement. Operating expenses were $5,997,151, and the company recorded a net loss of $2,115,831, or $0.13 per share.
Cash and cash equivalents were $28,129,866 as of September 30, 2025. Deferred collaboration revenue totaled $2,007,979. Shares outstanding were 16,742,638 as of quarter end; this is a baseline figure, not the amount being offered.
After quarter end, Coya completed an underwritten public offering of 4,181,818 shares at $5.50 per share for approximately $23.0 million in gross proceeds. Management states that existing cash together with these proceeds is expected to fund operations for at least one year after the statements are issued.
Coya Therapeutics held $29.8 million in cash and cash equivalents as of June 30, 2025 and reported an accumulated deficit of $54.1 million. The company recorded a net loss of $6.09 million for the three months and $13.40 million for the six months ended June 30, 2025. Collaboration revenue declined to $163,616 for the quarter and $421,500 for the six months, versus substantially higher amounts in the prior-year periods driven by upfront license recognition in 2024.
The balance sheet shows $1.372 million in deferred collaboration revenue. Under the DRL Development Agreement the company received a prior upfront payment of $7.5 million and $3.9 million in a June 2024 amendment; remaining R&D services revenue is being recognized over time. The company resubmitted an IND for COYA 302 on June 30, 2025 and disclosed the FDA told the company it cannot meet the initial review goal date but expects to provide a decision no later than August 29, 2025. Management states existing cash should fund operations for at least one year after issuance of these financial statements, and that substantial additional financing will be required thereafter.